Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers.

Abstract

The identification of tumor-associated/-specific antigens and an increased understanding of the ways in which antigens are processed and presented has led to a revived interest in cancer vaccines as a therapeutic strategy. BLP25 liposome (L-BLP25) vaccine is a cancer vaccine that targets the exposed core peptide of the MUC1 tumor-associated antigen. Studies in advanced-stage non-small cell lung cancer demonstrate that L-BLP25 vaccine has the potential to extend the survival of patients with Stage IIIB locoregional non-small cell lung cancer and maintain quality of life for longer. L-BLP25 vaccine also shows promise for prostate cancer patients, having the potential to prolong prostate-specific antigen doubling time in men with biochemical failure post prostatectomy. These clinically meaningful results with a relatively nontoxic therapeutic vaccine are very encouraging and suggest potential for L-BLP25 to fulfill an unmet medical need.

• Authors: Scott North, Charles Butts
• Journal: Expert review of vaccines (Expert Rev Vaccines) Vol. 4 Issue 3 Pg. 249-57 (Jun 2005) ISSN: 1744-8395 [Electronic] England
• PMID: 16026241 (Publication Type: Journal Article, Review)

Chemical References

• Cancer Vaccines
• Liposomes

Topics

• Animals
• Cancer Vaccines (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (immunology, prevention & control)
• Humans
• Liposomes
• Lung Neoplasms (immunology, prevention & control)
• Male
• Prostatic Neoplasms (immunology, prevention & control)